Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dermira
Biotech
Lilly’s $1B bet yields 'compelling' data on Dupixent rival
Analysts at Jefferies called the data compelling, although a hoped-for point of differentiation over the blockbuster incumbent has weakened.
Nick Paul Taylor
Mar 28, 2022 7:40am
Evommune snags $83M for "Tylenol for itch," three other programs
Sep 9, 2021 7:30am
Aslan hires Kobayashi to add IL-13 clinical trial expertise
Aug 3, 2020 8:56am
Pfizer’s Dupixent rival makes the grade in phase 3—again
Mar 18, 2020 8:44pm
Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout
Jan 10, 2020 8:20am
Pfizer's JAK inhibitor hits the mark in another eczema trial
Sep 27, 2019 11:11am
